Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Clinical outcome of Turkish metastatic breast cancer patients with currently available treatment modalities--single center experience.

Cabuk D, Basaran G, Teomete M, Dane F, Korkmaz T, Seber S, Telli F, Yumuk PF, Turhal S.

Asian Pac J Cancer Prev. 2014;15(1):117-22.

2.

Prognostic factors of brain metastases from breast cancer: impact of targeted therapies.

Braccini AL, Azria D, Thezenas S, Romieu G, Ferrero JM, Jacot W.

Breast. 2013 Oct;22(5):993-8. doi: 10.1016/j.breast.2013.05.011.

PMID:
23831232
3.

Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.

Arslan UY, Turker I, Aksoy S, Oksuzoglu B, Helvaci K, Yildirim Ozdemir N, Uyeturk U, Uysal Sonmez O, Budakoglu B, Zengin N.

J BUON. 2013 Jul-Sep;18(3):585-93.

PMID:
24065468
4.

Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry.

Inwald EC, Koller M, Klinkhammer-Schalke M, Zeman F, Hofstädter F, Lindberg P, Gerstenhauer M, Schüler S, Treeck O, Ortmann O.

J Cancer Res Clin Oncol. 2015 Dec;141(12):2229-40. doi: 10.1007/s00432-015-2025-z.

5.

[Clinical value of trastuzumab in the treatment of lapatinib-resistant HER2-positive metastatic breast cancer].

Ma F, Xu BH, Li HH, Li Q, Zhang P, Yuan P, Wang JY, Fan Y, Li Q.

Zhonghua Zhong Liu Za Zhi. 2013 Jul;35(7):521-4. Chinese.

PMID:
24257305
6.

Trastuzumab-containing regimens for metastatic breast cancer.

Balduzzi S, Mantarro S, Guarneri V, Tagliabue L, Pistotti V, Moja L, D'Amico R.

Cochrane Database Syst Rev. 2014 Jun 12;(6):CD006242. doi: 10.1002/14651858.CD006242.pub2. Review.

PMID:
24919460
7.

Capecitabine/cisplatin doublet in anthracycline and taxane pretreated and HER-2 negative metastatic breast carcinoma patients.

Ozdemir N, Aksoy S, Sendur MA, Akinci MB, Yazici O, Budakoglu B, Abali H, Oksuzoglu B, Zengin N.

J BUON. 2013 Oct-Dec;18(4):831-7.

PMID:
24344005
8.

[Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].

Zhang P, Xu BH, Ma F, Li Q, Yuan P, Wang JY, Zhang P.

Zhonghua Zhong Liu Za Zhi. 2011 May;33(5):381-4. Chinese.

PMID:
21875471
9.

Trends in survival for patients with metastatic breast cancer: is survival improving?

Giuliani J, Bonetti A.

Tumori. 2015 Jul-Aug;101(4):347-52. doi: 10.5301/tj.5000301.

PMID:
25953444
10.

The actual scenario of neoadjuvant chemotherapy of breast cancer in developing country: a report of 80 cases of breast cancer from a tertiary cancer center in India.

Das U, Lakshmaiah KC, Govind Babu K, Suresh TM, Lokanatha D, Jacob L, Babu S.

J Cancer Res Clin Oncol. 2014 Oct;140(10):1777-82. doi: 10.1007/s00432-014-1724-1.

PMID:
24894013
11.

Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.

Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, Ellis C, Florance A, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J.

J Clin Oncol. 2012 Jul 20;30(21):2585-92. doi: 10.1200/JCO.2011.35.6725.

PMID:
22689807
12.

Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial.

Metzger-Filho O, Procter M, de Azambuja E, Leyland-Jones B, Gelber RD, Dowsett M, Loi S, Saini KS, Cameron D, Untch M, Smith I, Gianni L, Baselga J, Jackisch C, Bell R, Sotiriou C, Viale G, Piccart-Gebhart M.

J Clin Oncol. 2013 Jun 1;31(16):1954-60. doi: 10.1200/JCO.2012.46.2440.

PMID:
23589556
13.

Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer.

Gori S, Montemurro F, Spazzapan S, Metro G, Foglietta J, Bisagni G, Ferzi A, Silva RR, Gamucci T, Clavarezza M, Stocchi L, Fabi A, Cognetti F, Torrisi E, Crivellari D.

Ann Oncol. 2012 Jun;23(6):1436-41. doi: 10.1093/annonc/mdr474.

PMID:
22039084
14.

Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: clinicopathological features, efficacy, and factors affecting survival.

Ulas A, Kos T, Avci N, Cubukcu E, Olmez OF, Bulut N, Degirmenci M.

Asian Pac J Cancer Prev. 2015;16(4):1643-9.

15.

Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study.

Kaufman PA, Brufsky AM, Mayer M, Rugo HS, Tripathy D, Yood MU, Feng S, Wang LI, Quah CS, Yardley DA.

Breast Cancer Res Treat. 2012 Oct;135(3):875-83. doi: 10.1007/s10549-012-2209-z.

16.

Impact of HER-2-targeted therapy on overall survival in patients with HER-2 positive metastatic breast cancer.

Berghoff AS, Bago-Horvath Z, Dubsky P, Rudas M, Pluschnig U, Wiltschke C, Gnant M, Steger GG, Zielinski CC, Bartsch R.

Breast J. 2013 Mar-Apr;19(2):149-55. doi: 10.1111/tbj.12070.

PMID:
23350584
17.

Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.

Rossi V, Nolè F, Redana S, Adamoli L, Martinello R, Aurilio G, Verri E, Sapino A, Viale G, Aglietta M, Montemurro F.

Breast. 2014 Feb;23(1):44-9. doi: 10.1016/j.breast.2013.10.005.

PMID:
24210572
18.

AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.

Gianni L, Romieu GH, Lichinitser M, Serrano SV, Mansutti M, Pivot X, Mariani P, Andre F, Chan A, Lipatov O, Chan S, Wardley A, Greil R, Moore N, Prot S, Pallaud C, Semiglazov V.

J Clin Oncol. 2013 May 10;31(14):1719-25. doi: 10.1200/JCO.2012.44.7912.

PMID:
23569311
19.

Pathological response and survival after neoadjuvant therapy for breast cancer: a 30-year study.

Guiu S, Arnould L, Bonnetain F, Dalban C, Favier L, Desmoulins I, Créhange G, Coutant C, Fumoleau P, Coudert B.

Breast. 2013 Jun;22(3):301-8. doi: 10.1016/j.breast.2012.07.012.

PMID:
22863283
20.

Prolonged clinical benefit from the maintenance hormone therapy in patients with metastatic breast cancer.

Lim S, Lee S, Han J, Park BW, Kim S, Park S, Kim JH, Choi HJ, Sohn J.

Breast. 2013 Dec;22(6):1205-9. doi: 10.1016/j.breast.2013.08.013.

PMID:
24135766
Items per page

Supplemental Content

Support Center